Although a strong predictor, the survival benefit presented by the methylated MGMT promoter compared to its unmethylated counterpart is lower than the benefit of having an IDH-1 Mutant GBM over an IDH-Wildtype GBM. The gene discussed is IDH1; the disease is glioblastoma.